Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 22:11:702.
doi: 10.3389/fimmu.2020.00702. eCollection 2020.

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward

Affiliations
Review

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward

Leila Jafarzadeh et al. Front Immunol. .

Abstract

CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments. CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments.

Keywords: T cells; cancer immunotherapy; chimeric antigen receptor; persistence; tumor microenvironment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Novel modifications in cytokine recipe and their receptors to enhance CAR T cell persistence.
Figure 2
Figure 2
Novel molecular signaling targets to improve CAR T cell persistence.
Figure 3
Figure 3
Novel strategies to enhance the persistence of CAR T cells. The overall aim of these approaches is to improve intrinsic CAR T cell fitness and allow to elicit optimal CAR T cell persistence in the setting of many intrinsic and/or extrinsic barriers operative within a harsh tumor microenvironment.

References

    1. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. (2002) 25:243 10.1097/00002371-200205000-00007 - DOI - PMC - PubMed
    1. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukocyte Biol. (2003) 74:961–5. 10.1189/jlb.0603272 - DOI - PubMed
    1. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. (2006) 311:1924–7. 10.1126/science.1122927 - DOI - PubMed
    1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. (1999) 17:2105–. 10.1200/JCO.1999.17.7.2105 - DOI - PubMed
    1. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. (2000) 6:S55–7. - PubMed

Publication types